Novo is paying Gensaic up to $354 million per target in upfront fees and development and commercial milestones, plus tiered ...

Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for ...

Gensaic partnership with Novo Nordisk, worth up to $354M, aims to develop next-generation precision therapies using novel protein design technology.